DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

Food and Drug Administration

[FR Doc. 02–23246 Filed 9–11–02; 8:45 am]
BILLING CODE 4120–03–P

Assessing Acrylamide in the U.S. Food Supply; Public Meeting; Draft Action Plan on Acrylamide; Availability

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice of public meeting and availability.

SUMMARY: The Food and Drug Administration (FDA) is announcing a public meeting entitled "Assessing Acrylamide in the U.S. Food Supply." The purpose of the public meeting is to update the public on FDA’s activities related to acrylamide in food, to present FDA’s draft action plan on acrylamide, and to obtain and solicit comments on the action plan.

Date and Time: The public meeting will be held on September 30, 2002, from 9 a.m. to 5 p.m.

Location: The public meeting will be held at the Food Safety and Applied Nutrition, Food and Drug Administration, Harvey W. Wiley Building Auditorium, 5100 Paint Branch Pkwy, College Park, MD.

Contact: Louis J. Carson, Food Safety Staff (HFS–32), Center for Food Safety and Applied Nutrition, Food and Drug Administration, 5100 Paint Branch Pkwy, College Park, MD 20740, 301–436–2130, FAX: 301–436–2605, e-mail: Louis.Carson@cfesan.fda.gov.

Addresses: Submit written comments concerning the agency’s draft action plan on acrylamide to the Dockets Management Branch (HFA–305), Food and Drug Administration, 5630 Fords Lane, rm. 1061, Rockville, MD 20852 by October 30, 2002. Submit electronic comments to http://www.fda.gov/dockets/ecomments. The draft action plan will be available on the Internet at http://www.cfsan.fda.gov/list.html.

Registration and Request for Oral Presentations: Send registration information (including name, title, firm name, address, telephone number, and fax number) to the contact person by September 26, 2002. Additionally, if you wish to make an oral presentation specify in your name and address, telephone number, and fax number to the contact person at least 7 days in advance.

Transcripts: Transcripts of the meeting may be requested in writing from the Freedom of Information Office (HFI–35), Food and Drug Administration, 5600 Fihers Lane, rm 12A–16, Rockville, MD 20857, approximately 15 working days after the meeting at a cost of $0.25 per page.

If you need special accommodations due to a disability, please notify the contact person at least 7 days in advance.

SUPPLEMENTARY INFORMATION:

I. Background

On April 24, 2002, researchers at the Swedish National Food Administration and Stockholm University reported finding the chemical acrylamide in a variety of fried and oven baked foods. The initial Swedish research indicates that acrylamide formation is particularly associated with traditional high temperature cooking processes for certain carbohydrate- rich foods (Ref. 1). Since the Swedish report, similar findings have been reported by Norway, the United Kingdom, and Switzerland. The discovery of acrylamide in foods is a concern because acrylamide is a potential human carcinogen and genotoxicant.

FDA is currently conducting a broad survey of the occurrence of acrylamide in foods. Analytical test methodology was developed for a broad range of food types by FDA to measure acrylamide levels. This methodology is available on the Internet at http://www.cfsan.fda.gov/dms/acrylami.html.

Preliminary FDA food analyses for acrylamide suggest that U.S. food levels are consistent with Swedish and European published findings.

Acrylamide is a potential cancer causing chemical that appears to be formed in many foods during the cooking process. It is not known if there is a link between acrylamide in food and cancer in humans. Further research into a number of factors will assist us in evaluating adequately the potential human risk of acrylamide. These factors include: Which foods contain acrylamide, range of levels in these foods, dietary exposure, the bioavailability of acrylamide from food, the potential of acrylamide to cause cancer when consumed in food, acrylamide’s potential to cause germ cell mutations, and biomarkers of acrylamide exposure.

Therefore, FDA has drafted an action plan to develop the information to assist effectively the risks associated with acrylamide in food and to make appropriate risk management choices.

II. Components of FDA’s Draft Action Plan on Acrylamide

The components of FDA’s draft action plan on acrylamide include:

• Assess the dietary exposure of U.S. consumers to acrylamide by measuring acrylamide levels in various foods.
• Develop screening methods and validate confirmatory methods of analysis.
• Assess the potential risks associated with acrylamide in foods by extensive evaluation of the available information and by expanding research into acrylamide toxicology.
• Identify mechanisms responsible for the formation of acrylamide in foods and identify means to reduce acrylamide exposure.
• Inform and educate consumers of the potential risks throughout the assessment process and as knowledge is gained.
• Develop and foster public/private partnerships to gather scientific and technological information and data for assessing the human risk.

This public meeting is intended to present FDA’s draft action plan on acrylamide and to obtain and solicit public comment on the plan. The draft action plan will be made public on the Internet at http://www.cfsan.fda.gov/
III. Comments

Interested persons may present data, information, or views orally or in writing on issues pending at the public meeting. Those desiring to make oral presentations should notify the contact person (see Contact) by September 26, 2002, and submit a brief statement of the general nature of the evidence or arguments they wish to present, their names, addresses, phone numbers, fax numbers, and e-mail addresses. Oral presentations are scheduled for the afternoon session starting at 1:30 p.m. Oral presentations may be limited to 5 minutes, but may be expanded based on the number of people wishing to comment.

You may submit written or electronic comments to the Dockets Management Branch (see ADDRESSES) for 30 days following the public meeting on the FDA’s acrylamide draft action plan. Two copies of any comments are to be submitted, except individuals may submit one copy. Comments should be identified with the docket number found in the brackets in the heading of this document. A copy of the document and received comments are available for public examination in the Dockets Management Branch between 9 a.m. and 4 p.m., Monday through Friday.

IV. Reference

The following reference has been placed on display in the Dockets Management Branch (see ADDRESSES) and may be seen by interested persons between 9 a.m. and 4 p.m., Monday through Friday.


Dated: September 6, 2002.
Margaret M. Dotzel, Associate Commissioner for Policy.

[FR Doc. 02–23193 Filed 9–9–02; 2:37 pm]